Roche Acquires Insulin Patch Pump Maker Medingo For Up To $200 Mil.
This article was originally published in The Pink Sheet Daily
Firm is ramping up production for expected 2012 launch of the Solo pump.
You may also be interested in...
The Swiss drug maker, long a leader in oncology, is vying to become a frontrunner in treating cardiovascular disease and metabolic disorders.
Developer of the Solo miniature insulin dispensing patch pump, which is 92% owned by diversified conglomerate Elron, could be sold for up to $213 million, including milestone payments, based on a "non-binding indication of interest" from an un-named third party, Elron says Oct. 26. But a Medingo deal would be subject to signing of a definitive agreement, and currently "there is no assurance of the occurrence, timing or terms of any such transaction," the firm says
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.